Garlic Extract Therapy in Children With Hypercholesterolemia

    loading  Checking for direct PDF access through Ovid



To determine whether garlic extract therapy is efficacious and safe in children with hypercholesterolemia.


Randomized, double-blind, placebo-controlled clinical trial.


Specialized pediatric lipid disorders ambulatory clinic.


Thirty pediatric patients, aged 8 to 18 years, who had familial hyperlipidemia and a minimum fasting total cholesterol level greater than 4.8 mmol/L (>185 mg/dL).


An 8-week course of a commercially available garlic extract (Kwai [Lichtwer Pharma, Berlin, Germany], 300 mg, 3 times a day) or an identical placebo.

Main Outcome Measures

Absolute and relative changes in fasting lipid profile parameters.


The groups were equivalent at baseline and compliance was similar in the 2 groups (P=.45). There was no significant relative attributable effect of garlic extract on fasting total cholesterol (+0.6% [95% confidence interval, -5.8% to +6.9%]) or low-density lipoprotein cholesterol (-0.5% [95% confidence interval, -8.7% to +7.6%]). The lower limits of the confidence intervals did not include -10%, the minimum relative attributable effect believed to be clinically important. Likewise, no significant effect was seen on the levels of high-density lipoprotein, triglycerides, apolipoprotein B-100, lipoprotein(a), fibrinogen, homocysteine, or blood pressure. There was a small effect on apolipoprotein A-I (+10.0% [95% confidence interval, +1.2% to +16.5%] P=.03). There were no differences in adverse effects between groups.


Garlic extract therapy has no significant effect on cardiovascular risk factors in pediatric patients with familial hyperlipidemia.

Related Topics

    loading  Loading Related Articles